Physician profile
Robert E Rollins
NPI 1306544481
$1,783.72
in general payments reported to CMS, 2019-2025
11 companies · $786 in 2025
The $786 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $997 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,783.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $481.43 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $158.85 | 2025 | Spravato |
| Shield Therapeutics INC | $145.93 | 2024 | |
| Phathom Pharmaceuticals, INC. | $130.23 | 2024 | Voquezna |
| Alkermes, INC. | $126.69 | 2025 | Lybalvi |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Auvelity |
| Abbvie INC. | $123.72 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $123.66 | 2024 | Rexulti |
| Gilead Sciences, INC. | $123.66 | 2024 | Veklury |
| Mylan Specialty L.P. | $123.66 | 2024 | Yupelri |
| Viiv Healthcare Company | $120.89 | 2024 | Dovato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rollins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.